MESO Financials: Mesoblast Limited AI Analysis

Home

Stock

MESO

Financials

MESO Financial

Mesoblast Limited

$14.87

0.4%

$0.05

At close: Apr 06, 16:00:00 GMT-4

$14.87

Post-market: Apr 06, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$14.81

Open

$14.89

Day's Range

$14.77 - $15.04

52 week range

$9.61 - $21.5

Volume

102.7K

Avg.Volume

262.2K

Dividend yield

EPS (TTM)

-0.74

Market Cap

$1.9B

What is Mesoblast Limited?

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

MESO Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
Revenue	65	17	5	7	10	7
Revenue Growth (YoY)	1,200%	240%	-28.99%	-30%	43%	-78%
Cost of Revenue	27	5	15	27	30	32
Gross Profit	37	12	-9	-20	-20	-25
Selling, General & Admin	50	39	23	25	27	30
Research & Development	60	34	23	25	31	51
Operating Expenses	111	94	57	42	53	65
Other Non Operating Income (Expenses)	-2	0	--	--	--	--
Pretax Income	-93	-101	-88	-82	-91	-99
Income Tax Expense	0	0	0	0	0	0
Net Income	-94	-102	-87	-81	-91	-98
Net Income Growth	-9%	17%	7%	-11%	-7%	27%
Shares Outstanding (Diluted)	1,292.04	1,207.79	986.7	779.49	684.42	638.18
Shares Change (YoY)	13%	22%	27%	14%	7%	21%
EPS (Diluted)	-0.07	-0.08	-0.08	-0.1	-0.13	-0.15
EPS Growth	-19%	-5%	-15%	-21%	-14%	5%
Free Cash Flow	-60	-50	-48	-63	-65	-102
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	56.92%	70.58%	-180%	-285.71%	-200%	-357.14%
Operating Margin	-112.3%	-482.35%	-1,320%	-885.71%	-730%	-1,285.71%
Profit Margin	-144.61%	-600%	-1,739.99%	-1,157.14%	-910%	-1,400%
Free Cash Flow Margin	-92.3%	-294.11%	-960%	-900%	-650%	-1,457.14%
EBITDA	--	-82	-65	-61	-72	-89
EBITDA Margin	--	-482.35%	-1,300%	-871.42%	-720%	-1,271.42%
D&A For EBITDA	--	0	1	1	1	1
EBIT	-73	-82	-66	-62	-73	-90
EBIT Margin	-112.3%	-482.35%	-1,320%	-885.71%	-730%	-1,285.71%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Mesoblast Limited's key financial statements?



According to the latest financial statement (Form-10K), Mesoblast Limited has a total asset of $784, Net loss of $-102

What are the key financial ratios for MESO?



Mesoblast Limited's Current ratio is 4.19, has a Net margin is -600, sales per share of $0.01.

How is Mesoblast Limited's revenue broken down by segment or geography?



Mesoblast Limited largest revenue segment is Cell Technology Platform, at a revenue of 9,006,727 in the most earnings release.For geography, Australia, United States, Singapore, United Kingdom and Switzerland is the primary market for Mesoblast Limited, at a revenue of 9,006,727.

Is Mesoblast Limited profitable?



no, according to the latest financial statements, Mesoblast Limited has a net loss of $-102

Does Mesoblast Limited have any liabilities?



yes, Mesoblast Limited has liability of 187

How many outstanding shares for Mesoblast Limited?



Mesoblast Limited has a total outstanding shares of 1,279.93

Mesoblast Limited (MESO) Financial

MESO Stock Price Chart